Jagsonpal Pharmaceuticals Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹81 Cr +9.5% YoYSee revenue, profit and what management said. You are viewing Q2 FY26.
JP

Jagsonpal Pharmaceuticals Ltd

Q2 FY26Pharmaceuticals & Biotechnology

Jagsonpal Pharmaceuticals Q2 FY26 earnings call: Revenue & Margins

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹74Cr
−1.3% YoY
−2.6% QoQ
Net profit
₹13Cr
+18.2% YoY
+18.2% QoQ
Margin
22%
0 pp YoY
+3 pp QoQ

Jagsonpal Pharmaceuticals Ltd Q2 FY26 key numbers

Revenue
Growth has moderated recently due to strategic underperformance of a key product, Dydrogesterone, which dropped from Rs.40 crore to Rs.10 crore in 24 months.

As stated in Jagsonpal Pharmaceuticals Ltd's Q2 FY26 earnings call transcript · published 15 Jul 2026. Reported figures, not investment advice.

Price₹237
Market cap₹1.5K Cr
P/E31.8

The short version

Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year. Jagsonpal Pharmaceuticals targets about 10% overall revenue growth for the current fiscal year, with expectations of accelerated growth thereafter (Page 12).

From Jagsonpal Pharmaceuticals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year.
  • There is an expectation of accelerated growth beyond the current year, with more detailed guidance to be provided in the coming weeks.
  • These will contribute to future growth.
  • Growth has moderated recently due to strategic underperformance of a key product, Dydrogesterone, which dropped from Rs.40 crore to Rs.10 crore in 24 months.
  • The company will focus on launching products in more difficult categories requiring concept selling, aiming for slower but sustainable growth.

2 more points from Jagsonpal Pharmaceuticals Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Jagsonpal Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The management highlighted cautious new product launches, focusing on less crowded, difficult categories requiring concept selling for sustainable buildup rather than quick scale.
  • There is openness to inorganic growth via acquisitions, with funding capacity through cash reserves (~Rs.150 crores), quarterly cash flow (approx. Rs.15 crores), leveraging the balance sheet, and shareholder backing.
  • They prefer acquisitions within a moderate size, smaller than large peers like Torrent, but are confident to take bigger acquisition steps due to improved organizational capability.
  • The acquisition of Yash Pharma is cited as a successful strategic integration, boosting both growth and margins.

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Jagsonpal Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The discussion primarily focused on financial performance, growth strategy, product launches, acquisition, market presence, and operational aspects without reference to order books.

Jagsonpal Pharmaceuticals Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Jagsonpal Pharmaceuticals Ltd Q2 FY26 results — key figures

Jagsonpal Pharmaceuticals Ltd Q2 FY26 reported results vs Q2 FY25, ₹ crore
₹ CrQ2 FY26Q2 FY25YoYQ1 FY26QoQ
Revenue7475-1.3%76-2.6%
Operating profit (EBITDA)16160%14+14.3%
Operating margin22%22%0 pp19%+3 pp
Profit before tax1715+13.3%14+21.4%
Net profit (PAT)1311+18.2%11+18.2%
EPS (₹)1.891.73+9.2%1.62+16.7%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹81 Cr, net profit ₹13 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Pharmaceuticals & Biotechnology this season

  • Bajaj Healthcare (Q2 FY26)

    For HYE (Half Year Ending) Sept 2025, Total Income reported is ₹299.28 crore. Key investor presentation takeaways from Bajaj Healthcare Ltd's Q2 FY26 investor p

  • Infinium Pharma (Q2 FY26)

    Revenue from Operations for H1FY26: Rs 84.05 crore, a 1% YoY increase from Rs 82.98 crore in H1FY25 (Page 22). Key investor presentation takeaways from Infinium

  • Wanbury (Q2 FY26)

    Q2FY26 Revenue from Operations: ₹160.06 Crore . Key investor presentation takeaways from Wanbury Ltd's Q2 FY26 investor presentation — and how it ranks against

  • Balaxi Pharma (Q2 FY26)

    Revenue for Q2 FY26: ₹56.17 crore . Key investor presentation takeaways from Balaxi Pharma's Q2 FY26 investor presentation — and how it ranks against sector pee

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Jagsonpal Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Jagsonpal Pharmaceuticals Ltd Q2 FY26 results?

Jagsonpal Pharmaceuticals is targeting about 10% overall growth for the medium-term, including the current year. Jagsonpal Pharmaceuticals targets about 10% overall revenue growth for the current fiscal year, with expectations of accelerated growth thereafter (Page 12).

What is Jagsonpal Pharmaceuticals Ltd share price analysis?

Jagsonpal Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 31.8 with a market cap of ₹1,494 Cr. Investors should review the full earnings analysis for detailed insights.

Is Jagsonpal Pharmaceuticals Ltd planning capital expenditure?

- The management highlighted cautious new product launches, focusing on less crowded, difficult categories requiring concept selling for sustainable buildup rather than quick scale. - There is openness to inorganic growth via acquisitions, with funding capacity through cash reserves (~Rs.150 crores), quarterly cash flow (approx.

Keep Jagsonpal Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.